Navigation Links
PNP Therapeutics Meets Important Financial and Regulatory Objectives in Development of New Cancer Therapies
Date:3/10/2011

BIRMINGHAM, Ala., March 10, 2011 /PRNewswire/ -- PNP Therapeutics, Inc. — an early-stage Birmingham-based biopharmaceutical company created from research conducted at Southern Research Institute and The University of Alabama at Birmingham (UAB) — today announced that several major objectives have been reached in the development of its therapeutic technology platform and proprietary products for the treatment of cancer.

"A number of important regulatory and financial efforts came to fruition, enabling PNP Therapeutics to begin a crucial phase in product development," said Frank R. Hunt, chief executive officer of PNP Therapeutics, Inc.   "We are delighted that we accomplished these goals so we can continue moving our technology products forward."

According to Hunt, those objectives included:

  • Receiving FDA approval of its Investigational New Drug (IND) application which will now allow PNP to conduct its first-in-man studies;
  • Signing an agreement with UAB to conduct clinical trials at its Comprehensive Cancer Center;
  • Enrolling and treating the first clinical trials patient;
  • Closing on a second round of funding worth $1,217,635 from its original investors;
  • Gaining a commitment from Southern Research Institute to become a direct investor in the company; and
  • Being awarded a $245,000 grant from the federal government as part of its Qualifying Therapeutic Discovery Project.

At the center of PNP's Therapeutic System is a patented enzyme (E. coli purine nucleoside phosphorylase) which has been shown to work with a variety of well-characterized nucleoside prodrugs generating active metabolites with high levels of anti-tumor activity. PNP Therapeutics is the exclusive licensee of a comprehensive collection of patents that broadly and specifically cover the Company's technology. These patents are owned jointly by the University of Alabama at Birmingham Research Foundation and Southern Research Institute of Birmingham.

MORE

Many common cancers can become untreatable despite the best medical intervention and the highest standard of care; some are eventually fatal. Compounds that could kill tumors are typically much too toxic to administer systemically to an already debilitated cancer patient.

PNP's therapeutic strategy is based on the notion that solid tumors can be programmed to generate their own chemotherapy, causing their own self-destruction. This selectivity is achieved by producing the PNP enzyme directly within the tumor cells and facilitating the interaction between the enzyme and a circulating prodrug in a relatively enclosed environment — the tumor mass itself.

"We have shown that this mode of chemotherapeutic action is remarkably potent, abolishes otherwise refractory human cancers, and can be used safely because it is executed and confined within the tumor mass," said Hunt.

Persons interested in learning more about this PNP Therapeutics clinical trial can access the information at www.ClinicalTrials.gov.

ABOUT PNP THERAPEUTICS

PNP Therapeutics®, Inc. is an early-stage, biopharmaceutical company engaged in the development of a platform technology and proprietary products for the treatment of cancer. www.pnptherapeutics.com.   To learn more, please contact Frank Hunt at frankrhunt@aol.com or call 706-636-3049.


'/>"/>
SOURCE PNP Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Echo Therapeutics to Present at the ROTH 23rd Annual Growth Stock Conference
2. Amicus Therapeutics Announces FDA Agreement to Commence Phase 2 Study of AT2220 Co-administered with Enzyme Replacement Therapy for Pompe Disease
3. Allon Therapeutics CEO Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com
4. Halozyme Therapeutics to Host Fourth Quarter and 2010 Financial Results Conference Call on March 11
5. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
6. FDAs Office of New Drugs Meets With Cell Therapeutics on its Appeal on Pixantrone
7. Nile Therapeutics Receives Positive NASDAQ Panel Decision
8. Health Diagnostic Laboratory, Inc. (HDL, Inc.) Partners With Gamma Therapeutics to Offer Breakthrough Diagnostic Assay for Heart Attack and Stroke Risk
9. Nektar Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
10. Nektar Therapeutics President and CEO Howard W. Robin to Present at the 31st Annual Cowen and Company Healthcare Conference in Boston
11. Echo Therapeutics Receives Frost & Sullivans 2011 Technology Innovation Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... May 23, 2016 According ... Share, Development, Growth and Demand Forecast to 2022 ... Other), by Application (Drug Discovery and Development, Proteomics, ... (Pharmaceuticals, Life Science and Biotechnology, Academic and Research ... Research, the global mass spectrometry market ...
(Date:5/23/2016)... -- The World Health Organization (WHO) expanded the Intended Use ... aged 13 years, and above. Effective immediately, the PrePex device, ... adolescent males in the 14 priority countries in Southern and ... male circumcision device to receive WHO Prequalification on 31 May ... said: " The expanded use of PrePex for ...
(Date:5/23/2016)... UAE, May 23, 2016 Experts ... of Precision Medicine and the role of technology ...   The First International Conference of VPS-Penn Medicine ... distinguished patronage and presence of Sheikh Nahyan bin Mubarak Al ... in Precision Medicine, which helps provide personalized medicine and tailor-made ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... Serenity Recovery, ... another video highlighting one of the many supplemental program options offered at their ... a 5 th Degree Black Belt in the Shorin-ryu style of Karate that ...
(Date:5/25/2016)... ... May 25, 2016 , ... The Horizon Foundation for ... pilot initiative to improve oral health-related awareness, education, prevention and treatment for young ... providers and promote best practices in 10 New Jersey counties where dental health ...
(Date:5/25/2016)... ... 2016 , ... New studies published today by the ... states. The outcomes examined in these studies include recovery of physical health and ... medical care. , “The goal of the studies is to provide information about ...
(Date:5/25/2016)... ... May 25, 2016 , ... Cheryl Bowker of Bowker ... bestow: the Dick McKenna Good Hands Legacy Award. McKenna ran one of Allstate’s most ... continues to inspire all those who knew him. The award named for him is ...
(Date:5/25/2016)... ... ... Casa Velas, an adults-only boutique hotel in Puerto Vallarta, Mexico, introduces a ... wellness suites . The two 1,350 sq. ft. suites which debuted in late 2015 ... amenities, from a custom soap selection and in-suite exercise kit to a personal wellness ...
Breaking Medicine News(10 mins):